pharma

This means that only large pharma companies can foot the bill, here.

We are definitely not experts in regards to pharma (neither Alice or I have experience working in pharma) but our advisors include pharma consultants and senior scientists.

A lot of new drugs come from start up pharma companies, who are exclusively funded by investors, not the government.

Admittedly, they were a small unit intended to drive innovation within discovery at that pharma.

Big pharma wants everyone to think they're broken so they can sell more pills, so that is counteracting the progression towards accepting diversity.

If this were to happen in pharma, you would have deaths and lawsuits.

For the longest time I have been wondering when a pharma would try to patent Neem for tooth/other medicinal uses.

Come on, your NHS is probably as badly run than my Sécurité Sociale, and allergic to consider better alternatives if it's not big pharma approved.

What pharma can't do with science, they paper over with marketing.

I have been doing other things since 2004 and not following pharma and biotech closely.

By 2007 it had been at least tried in most major pharma companies and John Russell was writing about the Awkward Adolescence of Systems Biology.

First, the NIH can afford to take a shotgun approach to research funding which pharma can't take because the risks of loss are so much lower.

He mentions those are "cheap" but that's because the pharma industry was treating them as a charity case for the last six months.

Biotech startups with a computational method of target discovery that is "different from the norm at Big Pharma" have been around at least since the late 90s.

You bring up another good point about "Eroom's Law" in which pharma productivity is actually decreasing, and that article was actually one of the things that got us interested in trying to do something new.

The 1000X number should only be attached to "cheaper", and comes from in vivo and in vitro validation experiments we have done; our drug hit rate was almost 1000X higher than high-throughput screens from the literature, and our total spend to get to our one drug lead was almost that many times cheaper than what we learned that pharma spends.

They should and can tackle some hard problems and develop algorithms and methods that are difficult to pursue in Big Pharma.

In some industries (Pharma) it's really the only practical approach due to the extreme development costs (easily over 1B$) and often cheap production costs.